Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | BAD | Q92934 | 1/20 | 0.48 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281891 | 1.00 | SRC (0.53) | SRCBCL2L1BADSLC13A5MAPT | |
| Hydrochloric Acid SCHEMBL8017722 | 0.98 | SRC (0.51) | SRCBCL2L1BADSLC13A5MAPT | |
| Bromide SCHEMBL11832548 | 0.98 | SRC (0.51) | SRCBCL2L1BADSLC13A5MAPT | |
| SCHEMBL108394 | 0.88 | PARP1 (0.43) | SRCBCL2L1BADMAPTMEN1 | |
| Valine SCHEMBL11149275 | 0.80 | SRC (0.41) | SRCBCL2L1BADSLC13A5MAPT | |
| SCHEMBL1709122 | 0.76 | SRC (0.41) | SRCBCL2L1BADSLC13A5MAPT | |
| SCHEMBL5759503 | 0.76 | SRC (0.49) | SRCSLC13A5MAPTKDM4EMEN1 | |
| SCHEMBL17969105 | 0.76 | SRC (0.49) | SRCBCL2L1BADSLC13A5MAPT | |
| SCHEMBL342322 | 0.76 | SRC (0.49) | SRCBCL2L1BADSLC13A5MAPT | |
| SCHEMBL6359546 | 0.76 | SRC (0.53) | SRCSLC13A5MAPTKDM4EPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119702019-A | Catalyst for catalyzing selective hydrogenation of quinoline and preparation method thereof | 湘潭大学 | 2025-03-28 | — | — | CN | claimed |
| CN-109529907-B | Nitrogen-doped carbon material supported cobalt catalyst, preparation method thereof and application thereof in catalytic oxidation of N-heterocyclic compound | 中南民族大学 | 2021-10-15 | — | — | CN | claimed |
| CN-109529907-A | A kind of nitrogen-doped carbon material load cobalt catalyst and preparation method thereof and the application in N- heterocyclic compound catalysis oxidation | 中南民族大学 | 2019-03-29 | — | — | CN | claimed |
| EP-3394068-A1 | TDO2 INHIBITORS | Genentech, Inc. (US) | 2018-10-31 | — | — | EP | claimed |
| CN-108264589-A | Polypropylene catalyst component, preparation method thereof and polypropylene catalyst | 中国石油天然气股份有限公司 | 2018-07-10 | — | — | CN | claimed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | claimed |
| EP-1242403-B1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | claimed |
| EP-0103797-B1 | SUBSTITUTED BENZOXAZINE DERIVATIVES | BAYER AG (DE) | 1986-11-26 | — | — | EP | claimed |
| EP-0103797-A2 | Substituted benzoxazine derivatives | BAYER AG (DE) | 1984-03-28 | — | — | EP | claimed |
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-119931978-A | Application of monoamine oxidase as catalyst in preparation of quinoline nitrogen heterocyclic compound | 河北工业大学 | 2025-05-06 | — | — | CN | disclosed |
| CN-119702019-A | Catalyst for catalyzing selective hydrogenation of quinoline and preparation method thereof | 湘潭大学 | 2025-03-28 | — | — | CN | disclosed |
| EP-3601239-B1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-117427074-A | Application of tetrahydroquinolinol as iron death inhibitor in preparation of acute kidney injury drugs | 山东第一医科大学(山东省医学科学院) | 2024-01-23 | — | — | CN | disclosed |
| US-4537888-A | Substituted benzoxazine derivatives and fungicidal use | BAYER AKTIENGESELLSCHAFT (DE) | 1985-08-27 | — | — | US | disclosed |
| EP-0103797-A2 | Substituted benzoxazine derivatives | BAYER AG (DE) | 1984-03-28 | — | — | EP | disclosed |
| EP-0103797-A2 | Substituted benzoxazine derivatives | BAYER AG (DE) | 1984-03-28 | — | — | EP | disclosed |
| US-4335123-A | HYPOTENSIVE AGENTS, ANTIARRHYTHMIA AGENTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1982-06-15 | — | — | US | disclosed |
| EP-0025864-A1 | Tetrahydroquinoline derivatives, processes for their production, their use and pharmaceutical preparations containing them | CASSELLA Aktiengesellschaft (DE) | 1981-04-01 | — | — | EP | disclosed |
| US-4133954-A | FUNGICIDES | CIBA-GEIGY CORPORATION (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | SRC 85/4885BCL2L1 2966/4885BAD 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.